



19 May 2026

Sydney, Australia

Nyrada Receives Notice of Allowance for Xolatrip® US Patent

Nyrada Inc (ASX:NYR), a clinical stage drug discovery and development company focused on advancing treatments across a portfolio of indications through innovative Transient Receptor Potential Canonical (TRPC) ion channel inhibition, is pleased to announce receipt of a notice of allowance from the United States Patent and Trademark Office for its patent application covering the composition of matter of Xolatrip®.

Subject to payment of the issue fee, the granted patent will provide intellectual property protection within the United States over Xolatrip's chemical structure, with a 20-year term from the September 2024 filing date.

A composition of matter patent protects against the unauthorised manufacture, use, sale, or import of Xolatrip without Nyrada's approval. The US application forms part of a broader global patent portfolio filed by the Company across key jurisdictions including Australia, Europe, and Japan.

Nyrada CEO and Managing Director James Bonnar commented: "The receipt of this notice of allowance is a significant milestone for Nyrada and validates the novelty and inventiveness of Xolatrip. Robust intellectual property protection is fundamental to realising the full commercial value of Xolatrip, and this patent strengthens our position as we advance clinical development."

About Xolatrip

Xolatrip is a small-molecule inhibitor of TRPC3/6/7 channels designed to limit excessive Ca²⁺ entry related to multiple disease pathologies.

[A Phase I clinical trial to assess the safety, tolerability, and pharmacokinetics has been successfully completed](#) and a [Phase IIa clinical trial to assess safety and efficacy](#) has commenced, targeting patients with acute myocardial infarction. This trial will assess safety and explore preliminary efficacy in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing PCI.

There are currently no approved therapies that directly address ischemia and reperfusion injury. Xolatrip is designed to address this critical unmet medical need.



Program Links:

- PROTECT-MI website - <https://www.protect-mi.com>
- Corporate presentation/about MI - <https://bit.ly/4dDWNCz>
- Phase IIa factsheet - <https://bit.ly/4bcDIKj>
- Phase I results - <https://bit.ly/3NtOGzH>
- GLP study results - <https://bit.ly/4d8VYkX>
- Preclinical cardioprotection study 1a - <https://bit.ly/4sigwMZ>
- Preclinical cardioprotection study 1b - <https://bit.ly/4rmOsXn>
- Preclinical cardioprotection study 2 - <https://bit.ly/40jHpUg>
- Preclinical traumatic brain injury study - <https://bit.ly/40fhrRT>
- Preclinical stroke study - <https://bit.ly/4sygHmH>

-ENDS-



About Nyrada Inc.

Nyrada Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp[®], has shown efficacy in preclinical cardioprotection and neuroprotection models and has completed a first-in-human Phase I clinical trial. A Phase IIa clinical trial has commenced to assess the safety and preliminary efficacy of Xolatryp in reducing myocardial ischemia reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing PCI. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

www.nyrada.com

Authorised by James Bonnar, CEO and Managing Director, on behalf of the Board.

Investor & Media Enquiries:

Dimitri Burshtein

T: 0491 789 391

E: info@nyrada.com

Company Secretary:

David Franks

T: 02 8072 1400

E: David.Franks@atomicgroup.com.au

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.